Subscribe to RoboticOncology.com RSS Feed

MRI-Guided Prostate Biopsy Improves Accuracy and Patient Comfort

NEW YORK, NY--(Marketwired - Apr 7, 2014) - During trial, a new MRI-guided prostate biopsy yielded more targeted prostate tissue retrieval and improved diagnosis accuracy. The combined multiparametric magnetic resonance imaging (mpMRI) and magnetic resonance (MR) guided biopsy (MRGB) techniques reduced the incidence of low-risk prostate cancer diagnosis and improved overall detection of intermediate- to high-risk disease compared to the traditional biopsy method.

Currently, transrectal ultrasound is used to guide the collection of as many as
30 random prostate tissue samples. In contrast, the two-part biopsy uses mpMRI to visually assess the prostate and then, if necessary, MRGB to collect just two needle samples from the tumor-identified area. Leading robotic prostate surgeon, David B. Samadi, MD, believes the new test will improve the patient experience and, more importantly, prostate cancer diagnosis and treatment planning.

"The MRI biopsy gives us the opportunity for very targeted tissue sampling, a more comfortable patient, and more accurate results," said Dr. Samadi, Chairman of Urology and Chief of Robotic Surgery at Lenox Hill Hospital.

Based on findings from the Australian clinical trial, researchers believe the mpMRI will better serve men with prostate cancer by increasing the detection of intermediate-risk and high-risk disease. At the same time, men as a whole will benefit from a reduction in over testing and over diagnosis of low-risk, indolent cancer.

From July 2012 through January 2013, a total of 223 men with elevated prostate-specific antigen (PSA) levels participated in the biopsy study. All patients received the mpMRI biopsy and the traditional ultrasound-guided biopsy.

Findings showed three main benefits of mpMRI/MRGB over ultrasound biopsy:

  • 51 percent reduction in patient need for prostate biopsy
  • 89.4 percent reduction in low-risk prostate cancer diagnosis
  • 17.7 percent increased detection of intermediate/high-risk prostate cancer

"While overtreatment of prostate cancer is not ideal, the new test will require us to remain vigilant -- not all low-risk diagnoses can be ignored," said Dr. Samadi. "Patients must work closely with prostate cancer experts to determine the best course of treatment. Individual assessment of risk factors will continue to play a role in the decision about whether or not to undergo treatment, even for those with low-risk diagnosis."

Back to Press Releases


Bookmark Using:
Facebook Twitter LinkedIn Email Yahoo

Share on Facebook

Call to Make an Appointment With Dr. David Samadi:

1-212-365-5000

Click the contact link to learn how Dr. Samadi can help treat your prostate cancer and give you back your quality of life.

* The benefits of robotic surgery cannot be guaranteed as surgery is both patient and procedure specific. Previous surgical results do not guarantee future outcomes.




Testimonials
Joe G., USA

I put my life, and my quality of life in the hands of the best surgeon I could find, DR. David Samadi.  My surgery was October 19th, 2009. I was walking around a few hours after surgery. I went home the next day.

more..
Ron Safir

Dr. Samadi, you are obviously a masterful surgeon.  In addition to your individual talents, you are also a tremendous CEO.

more..
Martin K., Patchogue, NY

I was diagnosed with prostate cancer in January of 2014. After researching for a surgeon the name Dr. David Samadi kept coming up for his expertise and great results. I got an appointment and went in to see Dr. Samadi and was already convinced (from what I read) that I wanted my prostate removed.

more..
Rob

It has been nearly two weeks since Dr. Samadi performed my SMART prostatectomy!  Every day since the surgery  Dr. Samadi and his skill as a surgeon have soared in my estimation. I feel humbled and privileged to have experienced such great care.

more..